KRAS and cancer: Further mechanistic studies into the divergent responses following KRASG12C inhibitor treatment and transcriptional modulations controlling new KRAS synthesis in drug-induced quiescent cells will uncover new therapeutic targets and modalities to overcome adaptive resistance to current KRASG12C inhibitors.452 KRAS inhibitors often trigger a cytostatic response in cancer cells and targeting a quiescent cell state will strengthen tumor targeting and likely lead to tumor cell death to achieve durable and complete responses in cancer patients.